Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders for Galectin Therapeutics Inc., held on December 3, 2020. The company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol GALT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
The primary material event reported is the election of directors and the ratification of the independent auditor. All nominated directors were elected by the stockholders. The voting results for the election of directors are as follows:
- Gilbert F. Amelio, Ph.D.: 24,557,619 votes for; 787,632 votes withheld.
- James C. Czirr: 24,919,870 votes for; 425,381 votes withheld.
- Kary Eldred: 25,143,631 votes for; 201,620 votes withheld.
- Kevin D. Freeman: 25,071,285 votes for; 273,966 votes withheld.
- Joel Lewis: 25,137,720 votes for; 207,531 votes withheld.
- Gilbert S. Omenn, M.D., Ph.D.: 24,831,878 votes for; 513,373 votes withheld.
- Marc Rubin, M.D.: 23,556,066 votes for; 1,789,185 votes withheld.
- Elissa J. Schwartz, Ph.D.: 25,152,647 votes for; 192,604 votes withheld.
- Harold H. Shlevin, Ph.D.: 25,107,044 votes for; 238,207 votes withheld.
- Richard E. Uihlein, Chairman: 25,106,625 votes for; 238,626 votes withheld.
- Richard A. Zordani: 25,141,937 votes for; 203,314 votes withheld.
Additionally, stockholders ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2020. The vote was 44,001,967 for, 186,747 against, and 364,390 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure and qualifications of the newly elected directors, particularly noting the higher number of withheld votes for Marc Rubin, M.D.
- Confirm the engagement terms and scope of work for the newly ratified auditor, Cherry Bekaert LLP.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.